Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Original Article
Author Details :
Volume : 5, Issue : 3, Year : 2019
Article Page : 275-278
https://doi.org/10.18231/j.ijceo.2019.066
Abstract
Introduction: To assess intraocular pressure variation after intravitreal bevacizumab injection in patients with diabetic macular edema.
Materials and Methods: Our prospective study included 20 eyes of patients who received intravitreal injection of 0.05 ml bevacizumab as treatment option for diabetic macular edema. IOP was recorded before the injection, at 3 days, 1week, 1month and 2 months after the intravitreal injection.
Results: The mean intraocular pressure before injection was 17.28±3.04 mmHg. The mean IOP post bevacizumab at 3 days, 1 week, 1month and 2 months were 19.98± 3.23mmHg, 18.99±3.67 mmHg, 17.31±3.19 and 17.15±3.10 respectively. There was statistically significant elevation in IOP at 3 days post bevacizumab injection, which reinstated to baseline levels at final follow-up.
Conclusion: Our study indicate that intravitreal injection of bevacizumab is associated with short term IOP elevation.
Keywords: Bevacizumab, Clinically significant macular edema, Diabetic macular edema, GAT, IOP.
How to cite : Ashwini G, Maheshwar N, To evaluate the effect of intravitreal bevacizumab on intraocular pressure. Indian J Clin Exp Ophthalmol 2019;5(3):275-278
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.